By Nikolaj Skydsgaard, Jacob Gronholt-PedersenCOPENHAGEN (Reuters) – Denmark on Wednesday became the very first country to stop utilizing AstraZenecas COVID-19 vaccine completely over a prospective link to a unusual but major type of blood clot.FILE PHOTO: Staff member manages AstraZeneca COVID-19 vaccines in storage at Region Hovedstadens Vaccine Center, Copenhagen, Denmark February 11, 2021. Ritzau Scanpix/Liselotte Sabroe by means of REUTERSThe choice will push back the set up conclusion of Denmarks vaccination scheme to early August from July 25, health authorities said.But that new timeline presumes it will begin using the Johnson & & Johnson vaccine, whose rollout in Europe has actually been delayed over similar clotting concerns and the usage of which Denmark has suspended. That shot comprises around a 3rd of the countrys total contracted supply.Results of investigations into the AstraZeneca-associated blood embolisms “revealed genuine and major side-effects,” Danish health agency head Soren Brostrom informed a news briefing.” We have actually therefore picked to continue the vaccination program for all target groups without this vaccine.” Astrazeneca said it respected Denmarks choice and would continue to supply it with information to inform future decisions.” Implementation and rollout of the vaccine program is a matter for each nation to decide, based on local conditions,” the Anglo-Swedish business said.The European Unions drug guard dog stated last week it had discovered a possible link between the AstraZeneca vaccine and cerebral venous sinus apoplexy (CVST), a brain blood clot.It stated the threat of passing away from COVID-19 was much higher than the threat of mortality from uncommon adverse effects, but left it to specific states to make their own threat assessments and decide how to administer the vaccine.Many countries in Europe and in other places have resumed utilizing the shot, with some restricting it to particular age groups, mainly those aged above 50 or above 60. Brostrom said joint studies based on Danish and Norwegian health information estimated that one in 40,000 people vaccinated with the AstraZeneca shot might anticipate to experience this serious complication, with nothing conclusive associated to age or gender.He said Denmark had actually come far in inoculating the elderly population most at threat of contracting a major kind of the virus.Future target groups for vaccination had a lower danger of that. “This should be weighed versus the reality that we now have a known threat of serious harmful results … with the COVID-19 vaccine from AstraZeneca, despite the fact that the risk in absolute numbers is little.” So Denmarks decision need to solely be seen in a Danish context, and “I comprehend effectively why other countries will use it,” he said.Denmark was the very first country to initially suspend all use of the AstraZeneca vaccine in March over safety concerns.Almost one million of the countrys 5.8 million population have received their first shots, 77% getting Pfizer-BioNTechs vaccine, 7.8% Modernas and 15.3% AstraZenecas. Denmark is in the process of relieving restrictions after its everyday COVID-19 infection rate slowed to 500-600 from a number of thousand in December.Reporting by Nikolaj Skydsgaard and Jacob Gronholt-Pedersen; Editing by Hugh Lawson, Toby Chopra and John Stonestreet